PSS World Medical
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict PSS World Medical's revenues will contract -18.5% and EPS will wane -23.7%.
The average estimate for revenue is $430.1 million. On the bottom line, the average EPS estimate is $0.29.
Revenue details
Last quarter, PSS World Medical logged revenue of $420.8 million. GAAP reported sales were 7.4% higher than the prior-year quarter's $391.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, non-GAAP EPS came in at $0.25. GAAP EPS of $0.31 for Q2 were 16% lower than the prior-year quarter's $0.37 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 33.8%, 60 basis points better than the prior-year quarter. Operating margin was 6.4%, 130 basis points worse than the prior-year quarter. Net margin was 3.6%, 150 basis points worse than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $1.70 billion. The average EPS estimate is $1.08.
Investor sentiment
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 60 members out of 70 rating the stock outperform, and 10 members rating it underperform. Among 33 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 28 give PSS World Medical a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on PSS World Medical is hold, with an average price target of $21.69.
Is PSS World Medical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add PSS World Medical to My Watchlist.